Literature DB >> 17452375

Clinical features of the DOK7 neuromuscular junction synaptopathy.

Jacqueline Palace1, Daniel Lashley, John Newsom-Davis, Judy Cossins, Susan Maxwell, Robin Kennett, Sandeep Jayawant, Yuji Yamanashi, David Beeson.   

Abstract

Mutations in DOK7 have recently been shown to underlie a recessive congenital myasthenic syndrome (CMS) associated with small simplified neuromuscular junctions ('synaptopathy') but normal acetylcholine receptor and acetylcholinesterase function. We identified DOK7 mutations in 27 patients from 24 kinships. Mutation 1124_1127dupTGCC was common, present in 20 out of 24 kinships. All patients were found to have at least one allele with a frameshift mutation in DOK7 exon 7, suggesting that loss of function(s) associated with the C-terminal region of Dok-7 underlies this disorder. In 15 patients, we were able to study the clinical features in detail. Clinical onset was usually characterized by difficulty in walking developing after normal motor milestones. Proximal muscles were usually more affected than distal, leading to a 'limb-girdle' pattern of weakness; although ptosis was often present from an early age, eye movements were rarely involved. Patients did not show long-term benefit from anticholinesterase medication and sometimes worsened, and where tried responded to ephedrine. The phenotype can be distinguished from 'limb-girdle' myasthenia associated with tubular aggregates, where DOK7 mutations were not detected and patients respond to anticholinesterase treatments. CMS due to DOK7 mutations are common within our UK cohort and is likely to be under-diagnosed; recognition of the phenotype will help clinical diagnosis, targeted genetic screening and appropriate management.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17452375     DOI: 10.1093/brain/awm072

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  34 in total

1.  Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7.

Authors:  D Lashley; J Palace; S Jayawant; S Robb; D Beeson
Journal:  Neurology       Date:  2010-05-11       Impact factor: 9.910

2.  Beneficial effect of albuterol in congenital myasthenic syndrome with epsilon-subunit mutations.

Authors:  Menachem Sadeh; Xin-Ming Shen; Andrew G Engel
Journal:  Muscle Nerve       Date:  2011-06-30       Impact factor: 3.217

3.  An ocular motility conundrum.

Authors:  Elizabeth Margaret McElnea; Kirk Stephenson; Bernie Lanigan; Ian Flitcroft
Journal:  BMJ Case Rep       Date:  2014-10-27

4.  LG2 agrin mutation causing severe congenital myasthenic syndrome mimics functional characteristics of non-neural (z-) agrin.

Authors:  Ricardo A Maselli; Jose M Fernandez; Juan Arredondo; Carmen Navarro; Maian Ngo; David Beeson; Orla Cagney; D Colette Williams; Robert L Wollmann; Vladimir Yarov-Yarovoy; Michael J Ferns
Journal:  Hum Genet       Date:  2011-12-29       Impact factor: 4.132

5.  AAV9-DOK7 gene therapy reduces disease severity in Smn2B/- SMA model mice.

Authors:  Kevin A Kaifer; Eric Villalón; Caley E Smith; Madeline E Simon; Jose Marquez; Abigail E Hopkins; Toni I Morcos; Christian L Lorson
Journal:  Biochem Biophys Res Commun       Date:  2020-07-30       Impact factor: 3.575

Review 6.  Current status of the congenital myasthenic syndromes.

Authors:  Andrew G Engel
Journal:  Neuromuscul Disord       Date:  2011-11-21       Impact factor: 4.296

7.  Congenital myasthenic syndromes in Turkey: Clinical clues and prognosis with long term follow-up.

Authors:  Hacer Durmus; Xin-Ming Shen; Piraye Serdaroglu-Oflazer; Bulent Kara; Yesim Parman-Gulsen; Coskun Ozdemir; Joan Brengman; Feza Deymeer; Andrew G Engel
Journal:  Neuromuscul Disord       Date:  2017-11-28       Impact factor: 4.296

8.  Phenotype genotype analysis in 15 patients presenting a congenital myasthenic syndrome due to mutations in DOK7.

Authors:  A Ben Ammar; F Petit; N Alexandri; K Gaudon; S Bauché; A Rouche; D Gras; E Fournier; J Koenig; T Stojkovic; A Lacour; P Petiot; F Zagnoli; L Viollet; N Pellegrini; D Orlikowski; L Lazaro; X Ferrer; G Stoltenburg; M Paturneau-Jouas; F Hentati; M Fardeau; D Sternberg; D Hantaï; P Richard; B Eymard
Journal:  J Neurol       Date:  2009-12-11       Impact factor: 4.849

9.  Mutations in MUSK causing congenital myasthenic syndrome impair MuSK-Dok-7 interaction.

Authors:  Ricardo A Maselli; Juan Arredondo; Orla Cagney; Jarae J Ng; Jennifer A Anderson; Colette Williams; Bae J Gerke; Betty Soliven; Robert L Wollmann
Journal:  Hum Mol Genet       Date:  2010-04-06       Impact factor: 6.150

10.  Dok-7 myasthenia: phenotypic and molecular genetic studies in 16 patients.

Authors:  Duygu Selcen; Margherita Milone; Xin-Ming Shen; C Michel Harper; Anthony A Stans; Eric D Wieben; Andrew G Engel
Journal:  Ann Neurol       Date:  2008-07       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.